Literature DB >> 18175039

An investigation into the use of human papillomavirus type 16 virus-like particles as a delivery vector system for foreign proteins: N- and C-terminal fusion of GFP to the L1 and L2 capsid proteins.

Oliver P Windram1, Brandon Weber, Mohamed A Jaffer, Edward P Rybicki, Dionne N Shepherd, Arvind Varsani.   

Abstract

Development of vaccine strategies against human papillomavirus (HPV), which causes cervical cancer, is a priority. We investigated the use of virus-like particles (VLPs) of the most prevalent type, HPV-16, as carriers of foreign proteins. Green fluorescent protein (GFP) was fused to the N or C terminus of both L1 and L2, with L2 chimeras being co-expressed with native L1. Purified chimaeric VLPs were comparable in size ( approximately 55 nm) to native HPV VLPs. Conformation-specific monoclonal antibodies (Mabs) bound to the VLPs, thereby indicating that they possibly retain their antigenicity. In addition, all of the VLPs encapsidated DNA in the range of 6-8 kb.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18175039     DOI: 10.1007/s00705-007-0025-2

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  5 in total

1.  LDP12, a novel cell-permeable peptide derived from L1 capsid protein of the human papillomavirus.

Authors:  Jong-Eun Lee; Hyunjung Jade Lim
Journal:  Mol Biol Rep       Date:  2011-05-15       Impact factor: 2.316

2.  Characterization of an RNA aptamer against HPV-16 L1 virus-like particles.

Authors:  Ana Gabriela Leija-Montoya; María Luisa Benítez-Hess; Julia Dolores Toscano-Garibay; Luis Marat Alvarez-Salas
Journal:  Nucleic Acid Ther       Date:  2014-08-11       Impact factor: 5.486

3.  Furin Cleavage of L2 during Papillomavirus Infection: Minimal Dependence on Cyclophilins.

Authors:  Matthew P Bronnimann; Christine M Calton; Samantha F Chiquette; Shuaizhi Li; Mingfeng Lu; Janice A Chapman; Kristin N Bratton; Angela M Schlegel; Samuel K Campos
Journal:  J Virol       Date:  2016-06-24       Impact factor: 5.103

4.  Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.

Authors:  Mathieu Boxus; Michel Fochesato; Agnès Miseur; Emmanuel Mertens; Najoua Dendouga; Sarah Brendle; Karla K Balogh; Neil D Christensen; Sandra L Giannini
Journal:  J Virol       Date:  2016-06-24       Impact factor: 5.103

Review 5.  Engineered biological entities for drug delivery and gene therapy protein nanoparticles.

Authors:  Joan Domingo-Espín; Ugutz Unzueta; Paolo Saccardo; Escarlata Rodríguez-Carmona; José Luís Corchero; Esther Vázquez; Neus Ferrer-Miralles
Journal:  Prog Mol Biol Transl Sci       Date:  2011       Impact factor: 3.622

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.